XTalks

OCTOBER 8, 2024

In a statement , the Nobel Assembly said the laureates discovered a new class of non-coding RNA molecules that play a crucial role in gene regulation. Their breakthrough revealed a previously unknown mechanism by which genes are controlled that is essential for the development and function of multicellular organisms, including humans.

Regulation 52

Regulation Genetics Scientist RNA 52

pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. Since then others have followed suit, including BenevolentAI with its BEN-2293 candidate for atopic dermatitis and Insilico Medicine with idiopathic pulmonary fibrosis therapy SM001-055.

Genome 136

Genome Genomics Drugs RNA 136

Camargo

JULY 27, 2021

How and When to Incorporate PK Design into Your Gene Therapy Development Plan. It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. Gene Therapy Definition.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. We have been very impressed by their vision and the relevance of their platform.”.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

OCTOBER 2, 2020

Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tumours grow and mutate. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology.

Vaccination 59

Vaccination Vaccine Immune Response Drugs 59

FDA Law Blog

OCTOBER 24, 2024

Gibbs — A recent blog post focused on the potentially negative implications of the proposed Patent Eligibility Restoration Act (PERA) for manufacturers of generic drugs and biosimilar products. animal, viral, bacterial) DNA and RNA sequences. The concerns raised by PERA are not limited to these industries, however.

Gene 64

Gene DNA Genetics Gene Sequencing 64

pharmaphorum

AUGUST 28, 2020

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease. Meanwhile, five of 12 previously-untreated patients had 2-log (90%) or a greater reduction in HBV DNA. The drug is in phase 1/2 development.

Drugs 52

Drugs DNA Licensing Licensing 52

pharmaphorum

APRIL 28, 2022

Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery.

RNA 52

RNA Drug Delivery Engineer Gene Therapy 52

pharmaphorum

JANUARY 26, 2023

In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA. Understanding individual drug reactions and metabolism Pharmacogenomics is emerging as an important area.

Genome 129

Genome Genomics Genome Project Genetics 129

Roots Analysis

FEBRUARY 23, 2022

NGS has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to develop a better understanding of the cause and consequences of disease. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries. Players Engaged in the Domain.

Genetics 52

Genetics DNA RNA Reagent 52

Roots Analysis

FEBRUARY 21, 2022

Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. As per our analysis, majority of the kits use purified RNA / DNA as the input sample. Diverse Landscape of NGS Library Preparation Kits.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 110

FDA Approval Gene Therapy Gene Clinical Trials 110

World of DTC Marketing

FEBRUARY 7, 2021

Drug Discovery and Manufacturing: It helps in the initial screening of drug compounds to the predicted success rate based on biological factors. Measuring RNA, DNA quickly. Precision medicine or next-generation sequencing helps in the faster discovery of drugs and tailored medication for individual patients. .

Doctor 164

Doctor Doctors Drugs Marketing 164

Roots Analysis

MARCH 8, 2023

Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA.

RNA 52

RNA Drug Delivery DNA Development 52

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. There currently are drugs that do just that but now they’re in clinical trials for metastatic breast cancer as well. An enzyme involved in DNA repair can be the key to making chemotherapy more effective.

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Roots Analysis

SEPTEMBER 9, 2024

It is worth highlighting that in 2023 alone, close to 20 protein-based drugs were approved for the treatment of myriad of disease indications including oncological and metabolic disorders. This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

XTalks

APRIL 6, 2022

The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Cancerous cells and tumors release small fragments of DNA into the bloodstream called circulating tumour DNA (ctDNA). Photo source: Inivata. Around 85 percent of cases are non-small cell lung cancer (NSCLC).

DNA 103

DNA In-Vitro Doctor Doctors 103

pharmaphorum

AUGUST 5, 2021

Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against targets once considered “undruggable.” ” Bayer is paying $1.5 ” Bayer is paying $1.5 billion ($5.3

DNA 52

DNA Gene Therapy Protein Gene 52

Delveinsight

FEBRUARY 25, 2021

Beam adds to drug delivery stable with USD 120 Million GuideTx buy. The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site. GuideTx will aid Beam in developing LNP-based medicines.

DNA 52

DNA In-Vivo Genetics Medicine 52

pharmaphorum

OCTOBER 12, 2021

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track their symptoms. Vutrisiran is under regulatory review in Europe and the US, with decisions due in 2022.

RNA 52

RNA DNA Drugs Protein 52

Roots Analysis

DECEMBER 12, 2023

As a result, innovators came up with the idea of magic bullets, antibody drug conjugates (ADCs). It is comprised of three components, namely antibody, drug and linker. The antibody is conjugated to the drug via a linker molecule. Further, the drug / payloads used were also not enough cytotoxic to kill all the tumor cells.

Antibody 40

Antibody Drugs Manufacturing RNA 40

Roots Analysis

AUGUST 15, 2024

On the other hand, solutions available in the oncology molecular diagnostics market can identify cancer at a much earlier stage, in some cases, even before symptoms develop. PCR is a widely used technique in molecular diagnostics that amplifies small amounts of DNA or RNA to detectable levels.

Marketing 40

Marketing Genetics Genome Genomics 40

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. 21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc.

Clinical Development 52

Clinical Development Development Medicine Clinical Trials 52

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

The Pharma Data

OCTOBER 19, 2020

. “Innovation in cancer treatment is realized through collaboration, and the physicians and researchers at Emory’s Winship Cancer Institute have consistently shown their commitment to developing novel cancer therapies using this collaborative approach,” said Chadi Nabhan , M.D., Ramalingam , M.D.,

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

The Pharma Data

NOVEMBER 5, 2020

While we are just beginning to analyze the data and this is not the outcome we were hoping for, we firmly believe it was the right experiment to conduct, and the learnings will inform the field and our ongoing development programs.”. AB-729 is an RNA interference (RNAi) therapeutic. Source link.

Drugs 40

Drugs Clinical Trials Clinical Trials RNA 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments.

Clinical Trials 96

Clinical Trials Clinical Trials Trials FDA Approval 96

Delveinsight

DECEMBER 13, 2020

alcohol, certain drugs) and autoimmune diseases can also cause hepatitis. Due to hepatitis C, most people develop cirrhosis, or scarring of the liver, before liver cancer; about 5–25% of patients with chronic hepatitis C develop cirrhosis over 10–20 years. Research and development in Hepatitis. Pegylated INF-?2b

Genotype 52

Genotype FDA Approval DNA Drugs 52

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. But both drew on the mRNA technology developed by Katalin Kariko from the University of Pennsylvania and her collaborator Drew Weissman, an immunologist from Boston University.

Vaccination 111

Vaccination Vaccine Doctor Doctors 111

Pfizer

AUGUST 15, 2022

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

MARCH 22, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Development 52

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. It focuses on the discovery and development of RNA-targeted drugs.

RNA 130

RNA DNA Antibody Production 130

Pfizer

JANUARY 27, 2023

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

Marketing 75

Marketing Production Drugs Licensing 75

XTalks

DECEMBER 22, 2021

The development and widespread adoption of new technologies is key to revolutionizing the way we diagnose, prevent, treat and manage disease. The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. RNA in the Making.

Life Science 95

Life Science RNA Vaccination Vaccine 95